Avid Bioservices Inc (CDMO)

[entdoc]

cj, I just read the 9/9/14 PPHM conference call transcription. Thanks again. Most impressive IMO. Some of my take away:
King:
--a future goal is to touch on the dendritic cell vaccines as well as antigen-based vaccines;
--We have already started to see the fruits of these collaborations with very encouraging results in preclinical models of Melanoma, Colon Cancer, and most recently Breast Cancer when combining bavituximab with other immune checkpoint inhibitors
--regarding breast cancer: "the investigator has prepared a manuscript, which we expect to be submitted for publication shortly. It’s going to contain obviously the results previously, but in a fuller description..."So there will be new date obviously then?” Joe Shan: Yes.
--So, when we think about partnering we’re really looking at expanding into some of these new indications, and clearly Breast Cancer & Liver Cancer are right now are at the top of the list, based
--clinical data will eventually trump all that [e.g. absence of stock price gains, lack of public recognition], and that’s the reason executing on the Phase III SUNRISE trial is so important as a backbone to getting the recognition for this [Bavi] program
Liver:
--We are continued to be encouraged by the updates from the principal investor, Dr. Adam Yopp of the Univ. of Texas SW Medical Center in Dallas, and we look forward to his presentation of the full clinical results at a future conference. Meanwhile, as part this trial, we have been able to generate translational data showing immune changes in patient tumor samples which are consistent with the immuno-modulating mechanism observed in preclinical models.
--revisiting prior observations:
"We can go back quite a ways to published data where actually [Bavi works qyute well with] radiotherapy as an adjuvant and a vaccine if you will.